Mindset Pharma Announces its Next Generation Novel 5-MeO-DMT Psychedelic Analogs Demonstrate a Significantly Improved Safety Profile in Preclinical Results

Mindset’s next generation 5-MeO-DMT drug candidates have shown a significant decrease in serotonergic toxicity; results reaffirm superior efficacy and safety TORONTO, Aug. 31, 2021 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating optimized and patentable next-generation…

Source